XNAS 13 Oct, 2026 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.63 per share. | 02 Oct 2026 | 8,333 | 12,279 (0%) | 0% | 21.6 | 180,243 | - |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Sale of securities on an exchange or to another person at price $ 114.52 per share. | 02 Oct 2026 | 1,100 | 11,179 (0%) | 0% | 114.5 | 125,973 | - |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Sale of securities on an exchange or to another person at price $ 115.73 per share. | 02 Oct 2026 | 2,086 | 9,093 (0%) | 0% | 115.7 | 241,412 | - |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Sale of securities on an exchange or to another person at price $ 116.59 per share. | 02 Oct 2026 | 5,147 | 3,946 (0%) | 0% | 116.6 | 600,063 | - |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 01 Oct 2026 | 413 | 10,351 (0%) | 0% | 8.3 | 3,416 | - |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 115.54 per share. | 01 Oct 2026 | 413 | 9,938 (0%) | 0% | 115.5 | 47,717 | - |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 01 Oct 2026 | 24,587 | 34,525 (0%) | 0% | 8.3 | 203,334 | - |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 116.12 per share. | 01 Oct 2026 | 15,843 | 18,682 (0%) | 0% | 116.1 | 1,839,741 | - |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 116.55 per share. | 01 Oct 2026 | 8,744 | 9,938 (0%) | 0% | 116.6 | 1,019,143 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.56 per share. | 01 Oct 2026 | 810 | 6,493 (0%) | 0% | 13.6 | 10,984 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Sale of securities on an exchange or to another person at price $ 115.40 per share. | 01 Oct 2026 | 810 | 5,683 (0%) | 0% | 115.4 | 93,473 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.56 per share. | 01 Oct 2026 | 3,357 | 9,040 (0%) | 0% | 13.6 | 45,521 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.26 per share. | 01 Oct 2026 | 5,833 | 14,873 (0%) | 0% | 19.3 | 112,344 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Sale of securities on an exchange or to another person at price $ 115.70 per share. | 01 Oct 2026 | 4,446 | 10,427 (0%) | 0% | 115.7 | 514,389 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Sale of securities on an exchange or to another person at price $ 116.54 per share. | 01 Oct 2026 | 4,744 | 5,683 (0%) | 0% | 116.5 | 552,869 | - |
| Mr. G. Charles Robb | Chief Business Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Sep 2026 | 17,100 | 14,056 (0%) | 0% | 0 | - | |
| Mr. G. Charles Robb | Chief Business Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Sep 2026 | 5,000 | 20,571 (0%) | 0% | 0 | - | |
| Mr. G. Charles Robb | Chief Business Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Sep 2026 | 5,000 | 20,571 (0%) | 0% | 0 | - | |
| Mr. G. Charles Robb | Chief Business Officer | 17 Sep 2026 | 17,493 | 182,507 | - | - | Stock option (right to buy) | ||
| Mr. G. Charles Robb | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 17 Sep 2026 | 17,493 | 31,156 (0%) | 0% | 8.3 | 144,667 | Common Stock |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Sale of securities on an exchange or to another person at price $ 100.82 per share. | 16 Sep 2026 | 296 | 3,946 (0%) | 0% | 100.8 | 29,843 | Common Stock |
| Mr. James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 111.70 per share. | 15 Sep 2026 | 2,800 | 1,064,543 (0%) | 0% | 111.7 | 312,771 | Common Stock |
| Mr. James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 110.84 per share. | 15 Sep 2026 | 400 | 1,067,343 (0%) | 0% | 110.8 | 44,335 | Common Stock |
| Mr. James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 110.27 per share. | 15 Sep 2026 | 6,800 | 1,067,743 (0%) | 0% | 110.3 | 749,835 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.56 per share. | 14 Sep 2026 | 7,404 | 15,683 (0%) | 0% | 13.6 | 100,398 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | 14 Sep 2026 | 2,596 | 0 | - | - | Stock option (right to buy) | ||
| Mr. Joseph Douglas Lyon | See Remarks | Sale of securities on an exchange or to another person at price $ 114.12 per share. | 14 Sep 2026 | 2,188 | 5,683 (0%) | 0% | 114.1 | 249,686 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | Sale of securities on an exchange or to another person at price $ 113.32 per share. | 14 Sep 2026 | 7,812 | 7,871 (0%) | 0% | 113.3 | 885,261 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.35 per share. | 14 Sep 2026 | 2,596 | 8,279 (0%) | 0% | 11.4 | 29,465 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | 14 Sep 2026 | 7,404 | 4,167 | - | - | Stock option (right to buy) | ||
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 164 | 13,754 (0%) | 0% | 0 | Common Stock | |
| Mr. G. Charles Robb | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.38 per share. | 01 Sep 2026 | 91 | 13,663 (0%) | 0% | 113.4 | 10,318 | Common Stock |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 113.38 per share. | 01 Sep 2026 | 164 | 13,590 (0%) | 0% | 113.4 | 18,594 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 138 | 16,406 (0%) | 0% | 0 | Common Stock | |
| Mr. Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.38 per share. | 01 Sep 2026 | 102 | 16,304 (0%) | 0% | 113.4 | 11,565 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 113.38 per share. | 01 Sep 2026 | 138 | 16,268 (0%) | 0% | 113.4 | 15,646 | Common Stock |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 150 | 10,055 (0%) | 0% | 0 | Common Stock | |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 115.61 per share. | 01 Sep 2026 | 2,281 | 9,755 (0%) | 0% | 115.6 | 263,711 | Common Stock |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 114.71 per share. | 01 Sep 2026 | 10,989 | 12,036 (0%) | 0% | 114.7 | 1,260,568 | Common Stock |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 113.94 per share. | 01 Sep 2026 | 11,730 | 23,025 (0%) | 0% | 113.9 | 1,336,459 | Common Stock |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 01 Sep 2026 | 25,000 | 34,755 (0%) | 0% | 8.3 | 206,750 | Common Stock |
| Mr. Sean Maduck | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.38 per share. | 01 Sep 2026 | 117 | 9,938 (0%) | 0% | 113.4 | 13,265 | Common Stock |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 113.38 per share. | 01 Sep 2026 | 150 | 9,905 (0%) | 0% | 113.4 | 17,007 | Common Stock |
| Mr. Sean Maduck | See Remarks | 01 Sep 2026 | 25,000 | 66,986 | - | - | Stock option (right to buy) | ||
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 130 | 5,755 (0%) | 0% | 0 | Common Stock | |
| Mr. Joseph Douglas Lyon | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.38 per share. | 01 Sep 2026 | 72 | 5,683 (0%) | 0% | 113.4 | 8,163 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 113.38 per share. | 01 Sep 2026 | 130 | 5,625 (0%) | 0% | 113.4 | 14,739 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 164 | 4,313 (0%) | 0% | 0 | Common Stock | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 113.38 per share. | 01 Sep 2026 | 164 | 4,149 (0%) | 0% | 113.4 | 18,594 | Common Stock |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Grant, award, or other acquisition of securities at price $ 113.38 per share. | 01 Sep 2026 | 138 | 4,206 (0%) | 0% | 113.4 | 15,646 | Common Stock |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | 01 Sep 2026 | 58,333 | 141,667 | - | - | Stock option (right to buy) | ||
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Sale of securities on an exchange or to another person at price $ 115.44 per share. | 01 Sep 2026 | 1,225 | 4,242 (0%) | 0% | 115.4 | 141,413 | Common Stock |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Sale of securities on an exchange or to another person at price $ 114.58 per share. | 01 Sep 2026 | 5,621 | 5,467 (0%) | 0% | 114.6 | 644,042 | Common Stock |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Sale of securities on an exchange or to another person at price $ 113.72 per share. | 01 Sep 2026 | 1,606 | 11,088 (0%) | 0% | 113.7 | 182,632 | Common Stock |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Sale of securities on an exchange or to another person at price $ 112.40 per share. | 01 Sep 2026 | 974 | 12,694 (0%) | 0% | 112.4 | 109,474 | Common Stock |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Sale of securities on an exchange or to another person at price $ 111.37 per share. | 01 Sep 2026 | 1,537 | 13,668 (0%) | 0% | 111.4 | 171,181 | Common Stock |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Sale of securities on an exchange or to another person at price $ 110.70 per share. | 01 Sep 2026 | 23,770 | 15,205 (0%) | 0% | 110.7 | 2,631,349 | Common Stock |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Sale of securities on an exchange or to another person at price $ 109.35 per share. | 01 Sep 2026 | 23,600 | 38,975 (0%) | 0% | 109.4 | 2,580,674 | Common Stock |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.63 per share. | 01 Sep 2026 | 58,333 | 62,575 (0%) | 0% | 21.6 | 1,261,743 | Common Stock |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 113.38 per share. | 01 Sep 2026 | 102 | 4,242 (0%) | 0% | 113.4 | 11,565 | Common Stock |
| Mr. Roberto Wandenkolk Vieira | President, Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2026 | 138 | 4,344 (0%) | 0% | 0 | Common Stock | |
| Ms. Kimberly Park | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.49 per share. | 26 Aug 2026 | 30,000 | 30,000 (0%) | 0% | 13.5 | 404,700 | Common Stock |
| Ms. Kimberly Park | Director | 26 Aug 2026 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | ||
| Ms. Kimberly Park | Director | Sale of securities on an exchange or to another person at price $ 122.55 per share. | 26 Aug 2026 | 26,685 | 0 (0%) | 0% | 122.5 | 3,270,169 | Common Stock |
| Ms. Kimberly Park | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.09 per share. | 26 Aug 2026 | 3,315 | 26,685 (0%) | 0% | 122.1 | 404,728 | Common Stock |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.35 per share. | 25 Aug 2026 | 30,955 | 40,710 (0%) | 0% | 11.3 | 351,339 | Common Stock |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 126.06 per share. | 25 Aug 2026 | 5,870 | 9,755 (0%) | 0% | 126.1 | 739,965 | Common Stock |
| Mr. Sean Maduck | See Remarks | 25 Aug 2026 | 30,955 | 169,045 | - | - | Stock option (right to buy) | ||
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 125.47 per share. | 25 Aug 2026 | 25,085 | 15,625 (0%) | 0% | 125.5 | 3,147,355 | Common Stock |
| Mr. David L. Mahoney | Director | Sale of securities on an exchange or to another person at price $ 117.47 per share. | 18 Aug 2026 | 4,984 | 1,232,161 (1%) | 0% | 117.5 | 585,478 | Common Stock |
| Mr. David L. Mahoney | Director | Sale of securities on an exchange or to another person at price $ 119.64 per share. | 18 Aug 2026 | 400 | 1,133,539 (0%) | 0% | 119.6 | 47,855 | Common Stock |
| Mr. David L. Mahoney | Director | Sale of securities on an exchange or to another person at price $ 118.88 per share. | 18 Aug 2026 | 7,055 | 1,133,939 (0%) | 0% | 118.9 | 838,710 | Common Stock |
| Mr. David L. Mahoney | Director | Sale of securities on an exchange or to another person at price $ 118.24 per share. | 18 Aug 2026 | 91,167 | 1,140,994 (0%) | 0% | 118.2 | 10,779,367 | Common Stock |
| Mr. G. Charles Robb | Chief Business Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Aug 2026 | 125 | 13,426 (0%) | 0% | 0 | Common Stock | |
| Mr. G. Charles Robb | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 116.26 per share. | 17 Aug 2026 | 10,000 | 39,716 (0%) | 0% | 116.3 | 1,162,572 | Common Stock |
| Mr. James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 110.49 per share. | 14 Aug 2026 | 3,053 | 1,081,490 (0%) | 0% | 110.5 | 337,341 | Common Stock |
| Mr. James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 112.64 per share. | 14 Aug 2026 | 2,279 | 1,074,543 (0%) | 0% | 112.6 | 256,706 | Common Stock |
| Mr. James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 111.44 per share. | 14 Aug 2026 | 4,668 | 1,076,822 (0%) | 0% | 111.4 | 520,214 | Common Stock |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 114.49 per share. | 14 Aug 2026 | 3,664 | 9,755 (0%) | 0% | 114.5 | 419,491 | Common Stock |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 14 Aug 2026 | 3,664 | 13,419 (0%) | 0% | 8.3 | 30,301 | Common Stock |
| Mr. Sean Maduck | See Remarks | 14 Aug 2026 | 3,664 | 91,986 | - | - | Stock option (right to buy) | ||
| Mr. G. Charles Robb | Chief Business Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Aug 2026 | 11,530 | 13,551 (0%) | 0% | 0 | Common Stock | |
| Mr. G. Charles Robb | Chief Business Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Aug 2026 | 3,000 | 15,571 (0%) | 0% | 0 | Common Stock | |
| Mr. G. Charles Robb | Chief Business Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Aug 2026 | 3,000 | 15,571 (0%) | 0% | 0 | Common Stock | |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 114.52 per share. | 10 Aug 2026 | 1,031 | 9,755 (0%) | 0% | 114.5 | 118,068 | Common Stock |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 10 Aug 2026 | 1,031 | 10,786 (0%) | 0% | 8.3 | 8,526 | Common Stock |
| Mr. Sean Maduck | See Remarks | 10 Aug 2026 | 1,031 | 95,650 | - | - | Stock option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 113.18 per share. | 10 Aug 2026 | 11,530 | 8,755 (0%) | 0% | 113.2 | 1,304,933 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 10 Aug 2026 | 16,300 | 110,000 | - | - | Stock Option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 114.04 per share. | 10 Aug 2026 | 4,770 | 3,985 (0%) | 0% | 114.0 | 543,957 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 10 Aug 2026 | 16,300 | 20,285 (0%) | 0% | 21.7 | 352,895 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 04 Aug 2026 | 3,700 | 7,685 (0%) | 0% | 21.7 | 80,105 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 04 Aug 2026 | 3,700 | 126,300 | - | - | Stock Option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 113.12 per share. | 04 Aug 2026 | 3,700 | 3,985 (0%) | 0% | 113.1 | 418,562 | Common Stock |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 114.70 per share. | 03 Aug 2026 | 20,305 | 9,755 (0%) | 0% | 114.7 | 2,329,075 | Common Stock |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 03 Aug 2026 | 20,305 | 30,060 (0%) | 0% | 8.3 | 167,922 | Common Stock |
| Mr. Sean Maduck | See Remarks | 03 Aug 2026 | 20,305 | 96,681 | - | - | Stock option (right to buy) | ||
| Mr. Joseph Douglas Lyon | See Remarks | Sale of securities on an exchange or to another person at price $ 114.16 per share. | 03 Aug 2026 | 1,540 | 5,495 (0%) | 0% | 114.2 | 175,806 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 118.73 per share. | 30 Jul 2026 | 4,783 | 25,234 (0%) | 0% | 118.7 | 567,908 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 116.96 per share. | 30 Jul 2026 | 7,089 | 38,284 (0%) | 0% | 117.0 | 829,102 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 115.87 per share. | 30 Jul 2026 | 14,222 | 45,373 (0%) | 0% | 115.9 | 1,647,859 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 105.54 per share. | 30 Jul 2026 | 4,200 | 91,930 (0%) | 0% | 105.5 | 443,248 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.06 per share. | 30 Jul 2026 | 80,000 | 96,130 (0%) | 0% | 23.1 | 1,844,800 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | 30 Jul 2026 | 80,000 | 95,833 | - | - | Stock option (right to buy) | ||
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 120.68 per share. | 30 Jul 2026 | 1,001 | 16,130 (0%) | 0% | 120.7 | 120,796 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 119.95 per share. | 30 Jul 2026 | 8,103 | 17,131 (0%) | 0% | 119.9 | 971,939 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 117.93 per share. | 30 Jul 2026 | 8,267 | 30,017 (0%) | 0% | 117.9 | 974,951 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 114.96 per share. | 30 Jul 2026 | 15,477 | 59,595 (0%) | 0% | 115.0 | 1,779,237 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 113.18 per share. | 30 Jul 2026 | 4,700 | 75,072 (0%) | 0% | 113.2 | 531,941 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 110.95 per share. | 30 Jul 2026 | 600 | 79,772 (0%) | 0% | 111.0 | 66,570 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 110.03 per share. | 30 Jul 2026 | 2,202 | 80,372 (0%) | 0% | 110.0 | 242,282 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 108.46 per share. | 30 Jul 2026 | 400 | 82,574 (0%) | 0% | 108.5 | 43,384 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 106.96 per share. | 30 Jul 2026 | 8,956 | 82,974 (0%) | 0% | 107.0 | 957,892 | Common Stock |
| Mr. James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 86.78 per share. | 15 Jul 2026 | 1,079 | 1,093,464 (0%) | 0% | 86.8 | 93,633 | Common Stock |
| Mr. James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 89.49 per share. | 15 Jul 2026 | 1,978 | 1,084,543 (0%) | 0% | 89.5 | 177,007 | Common Stock |
| Mr. James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 88.81 per share. | 15 Jul 2026 | 2,974 | 1,086,521 (0%) | 0% | 88.8 | 264,122 | Common Stock |
| Mr. James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 87.74 per share. | 15 Jul 2026 | 3,969 | 1,089,495 (0%) | 0% | 87.7 | 348,223 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 86.78 per share. | 15 Jul 2026 | 7,919 | 48,211 (0%) | 0% | 86.8 | 687,179 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.06 per share. | 15 Jul 2026 | 24,167 | 56,130 (0%) | 0% | 23.1 | 557,291 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.26 per share. | 15 Jul 2026 | 15,833 | 31,963 (0%) | 0% | 19.3 | 304,944 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | 15 Jul 2026 | 15,833 | 4,167 | - | - | Stock option (right to buy) | ||
| Mr. Atabak Mokari | Chief Financial Officer | 15 Jul 2026 | 24,167 | 175,833 | - | - | Stock option (right to buy) | ||
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 89.43 per share. | 15 Jul 2026 | 101 | 16,130 (0%) | 0% | 89.4 | 9,032 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 88.30 per share. | 15 Jul 2026 | 3,520 | 16,231 (0%) | 0% | 88.3 | 310,822 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 87.89 per share. | 15 Jul 2026 | 28,460 | 19,751 (0%) | 0% | 87.9 | 2,501,244 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 93.11 per share. | 07 Jul 2026 | 19,048 | 4,937 (0%) | 0% | 93.1 | 1,773,481 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 07 Jul 2026 | 20,000 | 130,000 | - | - | Stock Option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 93.54 per share. | 07 Jul 2026 | 952 | 3,985 (0%) | 0% | 93.5 | 89,048 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 07 Jul 2026 | 20,000 | 23,985 (0%) | 0% | 21.7 | 433,000 | Common Stock |
| Mr. Sean Maduck | See Remarks | 01 Jul 2026 | 25,000 | 116,986 | - | - | Stock option (right to buy) | ||
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 89.31 per share. | 01 Jul 2026 | 11,175 | 9,755 (0%) | 0% | 89.3 | 998,033 | Common Stock |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 88.51 per share. | 01 Jul 2026 | 2,801 | 20,930 (0%) | 0% | 88.5 | 247,924 | Common Stock |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 87.33 per share. | 01 Jul 2026 | 11,024 | 23,731 (0%) | 0% | 87.3 | 962,780 | Common Stock |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 01 Jul 2026 | 25,000 | 34,755 (0%) | 0% | 8.3 | 206,750 | Common Stock |
| Mr. David L. Mahoney | Director | Sale of securities on an exchange or to another person at price $ 84.53 per share. | 17 Jun 2026 | 20,000 | 26,147 (0%) | 0% | 84.5 | 1,690,506 | Common Stock |
| Mr. James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 82.69 per share. | 16 Jun 2026 | 4,177 | 1,100,366 (0%) | 0% | 82.7 | 345,416 | Common Stock |
| Mr. James N. Wilson | Director | Sale of securities on an exchange or to another person at price $ 83.57 per share. | 16 Jun 2026 | 5,823 | 1,094,543 (0%) | 0% | 83.6 | 486,633 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.26 per share. | 15 Jun 2026 | 40,000 | 56,130 (0%) | 0% | 19.3 | 770,400 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | 15 Jun 2026 | 40,000 | 20,000 | - | - | Stock option (right to buy) | ||
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 82.50 per share. | 15 Jun 2026 | 2 | 16,130 (0%) | 0% | 82.5 | 165 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 81.81 per share. | 15 Jun 2026 | 19,483 | 16,132 (0%) | 0% | 81.8 | 1,593,889 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 80.94 per share. | 15 Jun 2026 | 11,081 | 35,615 (0%) | 0% | 80.9 | 896,923 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 80.02 per share. | 15 Jun 2026 | 9,434 | 46,696 (0%) | 0% | 80.0 | 754,924 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 02 Jun 2026 | 20,000 | 23,985 (0%) | 0% | 21.7 | 433,000 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 02 Jun 2026 | 20,000 | 150,000 | - | - | Stock Option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 70.60 per share. | 02 Jun 2026 | 20,000 | 3,985 (0%) | 0% | 70.6 | 1,412,000 | Common Stock |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 70.44 per share. | 01 Jun 2026 | 776 | 25,263 (0%) | 0% | 70.4 | 54,661 | Common Stock |
| Mr. G. Charles Robb | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.44 per share. | 01 Jun 2026 | 358 | 25,681 (0%) | 0% | 70.4 | 25,218 | Common Stock |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2026 | 776 | 26,039 (0%) | 0% | 0 | Common Stock | |
| Mr. Atabak Mokari | Chief Financial Officer | 01 Jun 2026 | 40,000 | 60,000 | - | - | Stock option (right to buy) | ||
| Mr. Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.44 per share. | 01 Jun 2026 | 395 | 16,130 (0%) | 0% | 70.4 | 27,824 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2026 | 634 | 16,525 (0%) | 0% | 0 | Common Stock | |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 70.44 per share. | 01 Jun 2026 | 634 | 15,891 (0%) | 0% | 70.4 | 44,659 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 70.00 per share. | 01 Jun 2026 | 40,000 | 15,257 (0%) | 0% | 70.0 | 2,800,004 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.26 per share. | 01 Jun 2026 | 40,000 | 55,257 (0%) | 0% | 19.3 | 770,400 | Common Stock |
| Mr. Sean Maduck | See Remarks | 01 Jun 2026 | 25,000 | 141,986 | - | - | Stock option (right to buy) | ||
| Mr. Sean Maduck | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.44 per share. | 01 Jun 2026 | 452 | 9,755 (0%) | 0% | 70.4 | 31,839 | Common Stock |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2026 | 615 | 10,207 (0%) | 0% | 0 | Common Stock | |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 70.44 per share. | 01 Jun 2026 | 615 | 9,592 (0%) | 0% | 70.4 | 43,321 | Common Stock |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 70.75 per share. | 01 Jun 2026 | 3,931 | 8,977 (0%) | 0% | 70.7 | 278,103 | Common Stock |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 70.11 per share. | 01 Jun 2026 | 21,069 | 12,908 (0%) | 0% | 70.1 | 1,477,080 | Common Stock |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 01 Jun 2026 | 25,000 | 33,977 (0%) | 0% | 8.3 | 206,750 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2026 | 537 | 7,304 (0%) | 0% | 0 | Common Stock | |
| Mr. Joseph Douglas Lyon | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 70.44 per share. | 01 Jun 2026 | 269 | 7,035 (0%) | 0% | 70.4 | 18,948 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 70.44 per share. | 01 Jun 2026 | 537 | 6,767 (0%) | 0% | 70.4 | 37,826 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2026 | 877 | 3,985 (0%) | 0% | 0 | Common Stock | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 70.44 per share. | 01 Jun 2026 | 877 | 3,108 (0%) | 0% | 70.4 | 61,776 | Common Stock |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.74 per share. | 29 May 2026 | 12,837 | 2,565,489 (2%) | 0% | 69.7 | 895,252 | Common Stock |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 150,000 | 150,000 (0%) | 0% | 0 | Common Stock | |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 150,000 | 150,000 (0%) | 0% | 0 | Common Stock | |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 29 May 2026 | 300,000 | 2,578,326 (2%) | 0% | 0 | Common Stock | |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 May 2026 | 892,056 | 9,011 (0%) | 0% | 0 | Common Stock | |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 May 2026 | 9,011 | 1,104,543 (0%) | 0% | 0 | Common Stock | |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 May 2026 | 9,011 | 0 (0%) | 0% | 0 | Common Stock | |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 65.37 per share. | 27 May 2026 | 54,575 | 29,402 (0%) | 0% | 65.4 | 3,567,628 | Common Stock |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 27 May 2026 | 75,000 | 83,977 (0%) | 0% | 8.3 | 620,250 | Common Stock |
| Mr. Sean Maduck | See Remarks | 27 May 2026 | 75,000 | 166,986 | - | - | Stock option (right to buy) | ||
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 66.16 per share. | 27 May 2026 | 20,425 | 8,977 (0%) | 0% | 66.2 | 1,351,316 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 27 May 2026 | 5,000 | 6,230 (0%) | 0% | 65 | 325,000 | Common Stock |
| Mr. G. Charles Robb | Chief Business Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 27 May 2026 | 600 | 25,081 (0%) | 0% | 0 | Common Stock | |
| Mr. David L. Mahoney | Director | 21 May 2026 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | ||
| Mr. Daniel N. Swisher,Jr | Director | 21 May 2026 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | ||
| Mr. George Leonard Baker, Jr | Director | 21 May 2026 | 12,500 | 12,500 | - | - | Stock Option (Right To Buy) | ||
| Dr. Gregg H. Alton, J.D. | Director | 21 May 2026 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | ||
| Mr. James N. Wilson | Director | 21 May 2026 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | ||
| Ms. Kimberly Park | Director | 21 May 2026 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | ||
| Mr. Joshua M. Murray | Director | 21 May 2026 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | ||
| Mr. G. Charles Robb | Chief Business Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 13 May 2026 | 5,300 | 24,487 (0%) | 0% | 0 | Common Stock | |
| Mr. G. Charles Robb | Chief Business Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 13 May 2026 | 1,000 | 12,571 (0%) | 0% | 0 | Common Stock | |
| Mr. G. Charles Robb | Chief Business Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 13 May 2026 | 1,000 | 12,571 (0%) | 0% | 0 | Common Stock | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 05 May 2026 | 20,000 | 170,000 | - | - | Stock Option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 51.83 per share. | 05 May 2026 | 20,000 | 2,231 (0%) | 0% | 51.8 | 1,036,600 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 05 May 2026 | 20,000 | 22,231 (0%) | 0% | 21.7 | 433,000 | Common Stock |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.10 per share. | 01 May 2026 | 40,000 | 2,878,326 (2%) | 0% | 50.1 | 2,003,860 | Common Stock |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Apr 2026 | 2,000 | 1,095,532 (0%) | 0% | 0 | Common Stock | |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Apr 2026 | 2,000 | 1,095,532 (0%) | 0% | 0 | - | |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 22 Apr 2026 | 2,000 | 1,095,532 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 07 Apr 2026 | 20,000 | 22,231 (0%) | 0% | 21.7 | 433,000 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 40.97 per share. | 07 Apr 2026 | 20,000 | 2,231 (0%) | 0% | 41.0 | 819,400 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 07 Apr 2026 | 20,000 | 22,231 (0%) | 0% | 21.7 | 433,000 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 40.97 per share. | 07 Apr 2026 | 20,000 | 2,231 (0%) | 0% | 41.0 | 819,400 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 07 Apr 2026 | 20,000 | 190,000 | - | - | Stock Option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 40.97 per share. | 07 Apr 2026 | 20,000 | 2,231 (0%) | 0% | 41.0 | 819,400 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 07 Apr 2026 | 20,000 | 22,231 (0%) | 0% | 21.7 | 433,000 | Common Stock |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Apr 2026 | 5,000 | 1,097,532 (0%) | 0% | 0 | Common Stock | |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Apr 2026 | 5,000 | 1,097,532 (0%) | 0% | 0 | - | |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 06 Apr 2026 | 5,000 | 1,097,532 (0%) | 0% | 0 | - | |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.07 per share. | 25 Mar 2026 | 26,198 | 2,918,326 (2%) | 0% | 50.1 | 1,311,826 | - |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.07 per share. | 25 Mar 2026 | 26,198 | 2,918,326 (2%) | 0% | 50.1 | 1,311,826 | - |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.07 per share. | 25 Mar 2026 | 26,198 | 2,918,326 (2%) | 0% | 50.1 | 1,311,826 | Common Stock |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Mar 2026 | 4,000 | 1,102,532 (0%) | 0% | 0 | Common Stock | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 36.01 per share. | 20 Mar 2026 | 11,767 | 2,231 (0%) | 0% | 36.0 | 423,730 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 20 Mar 2026 | 11,767 | 210,000 | - | - | Stock Option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 20 Mar 2026 | 11,767 | 13,998 (0%) | 0% | 21.7 | 254,756 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 20 Mar 2026 | 11,767 | 13,998 (0%) | 0% | 21.7 | 254,756 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 36.01 per share. | 20 Mar 2026 | 11,767 | 2,231 (0%) | 0% | 36.0 | 423,730 | - |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Mar 2026 | 4,000 | 1,102,532 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 20 Mar 2026 | 11,767 | 13,998 (0%) | 0% | 21.7 | 254,756 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 36.01 per share. | 20 Mar 2026 | 11,767 | 2,231 (0%) | 0% | 36.0 | 423,730 | - |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Mar 2026 | 4,000 | 1,102,532 (0%) | 0% | 0 | - | |
| Mr. George Leonard Baker, Jr | Director | Purchase of securities on an exchange or from another person at price $ 33.00 per share. | 17 Mar 2026 | 75,782 | 1,122,413 (0%) | 0% | 33.0 | 2,500,973 | - |
| Mr. George Leonard Baker, Jr | Director | Purchase of securities on an exchange or from another person at price $ 33.56 per share. | 17 Mar 2026 | 24,218 | 1,146,631 (1%) | 0% | 33.6 | 812,836 | - |
| Mr. George Leonard Baker, Jr | Director | Purchase of securities on an exchange or from another person at price $ 33.00 per share. | 17 Mar 2026 | 75,782 | 1,122,413 (0%) | 0% | 33.0 | 2,500,973 | - |
| Mr. George Leonard Baker, Jr | Director | Purchase of securities on an exchange or from another person at price $ 33.56 per share. | 17 Mar 2026 | 24,218 | 1,146,631 (1%) | 0% | 33.6 | 812,836 | - |
| Mr. George Leonard Baker, Jr | Director | Purchase of securities on an exchange or from another person at price $ 33.00 per share. | 17 Mar 2026 | 75,782 | 1,122,413 (0%) | 0% | 33.0 | 2,500,973 | Common Stock |
| Mr. George Leonard Baker, Jr | Director | Purchase of securities on an exchange or from another person at price $ 33.56 per share. | 17 Mar 2026 | 24,218 | 1,146,631 (1%) | 0% | 33.6 | 812,836 | Common Stock |
| Mr. David L. Mahoney | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.15 per share. | 13 Mar 2026 | 5,469 | 24,531 (0%) | 0% | 32.1 | 175,828 | Common Stock |
| Mr. David L. Mahoney | Director | Other type of transaction at price $ 0.00 per share. | 13 Mar 2026 | 24,531 | 1,237,145 (1%) | 0% | 0 | Common Stock | |
| Mr. David L. Mahoney | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Mar 2026 | 24,531 | 0 (0%) | 0% | 0 | Common Stock | |
| Mr. David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.86 per share. | 13 Mar 2026 | 30,000 | 30,000 (0%) | 0% | 5.9 | 175,800 | Common Stock |
| Mr. David L. Mahoney | Director | 13 Mar 2026 | 30,000 | 0 | - | - | Stock Option (right to buy) | ||
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Mar 2026 | 28,000 | 1,106,532 (0%) | 0% | 0 | Common Stock | |
| Mr. David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.86 per share. | 13 Mar 2026 | 30,000 | 30,000 (0%) | 0% | 5.9 | 175,800 | - |
| Mr. David L. Mahoney | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.15 per share. | 13 Mar 2026 | 5,469 | 24,531 (0%) | 0% | 32.1 | 175,828 | - |
| Mr. David L. Mahoney | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Mar 2026 | 24,531 | 0 (0%) | 0% | 0 | - | |
| Mr. David L. Mahoney | Director | Other type of transaction at price $ 0.00 per share. | 13 Mar 2026 | 24,531 | 1,237,145 (1%) | 0% | 0 | - | |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Mar 2026 | 28,000 | 1,106,532 (0%) | 0% | 0 | - | |
| Mr. David L. Mahoney | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.86 per share. | 13 Mar 2026 | 30,000 | 30,000 (0%) | 0% | 5.9 | 175,800 | - |
| Mr. David L. Mahoney | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.15 per share. | 13 Mar 2026 | 5,469 | 24,531 (0%) | 0% | 32.1 | 175,828 | - |
| Mr. David L. Mahoney | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Mar 2026 | 24,531 | 0 (0%) | 0% | 0 | - | |
| Mr. David L. Mahoney | Director | Other type of transaction at price $ 0.00 per share. | 13 Mar 2026 | 24,531 | 1,237,145 (1%) | 0% | 0 | - | |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Mar 2026 | 28,000 | 1,106,532 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 04 Mar 2026 | 8,233 | 10,464 (0%) | 0% | 21.6 | 178,244 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 35.99 per share. | 04 Mar 2026 | 8,233 | 2,231 (0%) | 0% | 36.0 | 296,346 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 04 Mar 2026 | 8,233 | 10,464 (0%) | 0% | 21.6 | 178,244 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 35.99 per share. | 04 Mar 2026 | 8,233 | 2,231 (0%) | 0% | 36.0 | 296,346 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 04 Mar 2026 | 8,233 | 221,767 | - | - | Stock Option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 35.99 per share. | 04 Mar 2026 | 8,233 | 2,231 (0%) | 0% | 36.0 | 296,346 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 04 Mar 2026 | 8,233 | 10,464 (0%) | 0% | 21.6 | 178,244 | Common Stock |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 499 | 79,125 (0%) | 0% | 36.0 | 17,949 | Common Stock |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 499 | 79,624 (0%) | 0% | 0 | Common Stock | |
| Mr. G. Charles Robb | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 121 | 79,503 (0%) | 0% | 36.0 | 4,352 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 96 | 15,257 (0%) | 0% | 36.0 | 3,453 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 397 | 14,956 (0%) | 0% | 36.0 | 14,280 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 397 | 15,353 (0%) | 0% | 0 | Common Stock | |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 454 | 8,633 (0%) | 0% | 36.0 | 16,330 | Common Stock |
| Mr. Sean Maduck | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 110 | 8,977 (0%) | 0% | 36.0 | 3,957 | Common Stock |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 454 | 9,087 (0%) | 0% | 0 | Common Stock | |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 398 | 10,921 (0%) | 0% | 36.0 | 14,316 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 89 | 11,230 (0%) | 0% | 36.0 | 3,201 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 398 | 11,319 (0%) | 0% | 0 | Common Stock | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 498 | 1,733 (0%) | 0% | 36.0 | 17,913 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 498 | 2,231 (0%) | 0% | 0 | Common Stock | |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 398 | 10,921 (0%) | 0% | 36.0 | 14,316 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 398 | 11,319 (0%) | 0% | 0 | - | |
| Mr. Joseph Douglas Lyon | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 89 | 11,230 (0%) | 0% | 36.0 | 3,201 | - |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 397 | 14,956 (0%) | 0% | 36.0 | 14,280 | - |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 397 | 15,353 (0%) | 0% | 0 | - | |
| Mr. Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 96 | 15,257 (0%) | 0% | 36.0 | 3,453 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 498 | 1,733 (0%) | 0% | 36.0 | 17,913 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 498 | 2,231 (0%) | 0% | 0 | - | |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 499 | 79,125 (0%) | 0% | 36.0 | 17,949 | - |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 499 | 79,624 (0%) | 0% | 0 | - | |
| Mr. G. Charles Robb | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 121 | 79,503 (0%) | 0% | 36.0 | 4,352 | - |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 454 | 8,633 (0%) | 0% | 36.0 | 16,330 | - |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 454 | 9,087 (0%) | 0% | 0 | - | |
| Mr. Sean Maduck | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 110 | 8,977 (0%) | 0% | 36.0 | 3,957 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 398 | 10,921 (0%) | 0% | 36.0 | 14,316 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 398 | 11,319 (0%) | 0% | 0 | - | |
| Mr. Joseph Douglas Lyon | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 89 | 11,230 (0%) | 0% | 36.0 | 3,201 | - |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 397 | 14,956 (0%) | 0% | 36.0 | 14,280 | - |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 397 | 15,353 (0%) | 0% | 0 | - | |
| Mr. Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 96 | 15,257 (0%) | 0% | 36.0 | 3,453 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 498 | 1,733 (0%) | 0% | 36.0 | 17,913 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 498 | 2,231 (0%) | 0% | 0 | - | |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 499 | 79,125 (0%) | 0% | 36.0 | 17,949 | - |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 499 | 79,624 (0%) | 0% | 0 | - | |
| Mr. G. Charles Robb | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 121 | 79,503 (0%) | 0% | 36.0 | 4,352 | - |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 35.97 per share. | 02 Mar 2026 | 454 | 8,633 (0%) | 0% | 36.0 | 16,330 | - |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 454 | 9,087 (0%) | 0% | 0 | - | |
| Mr. Sean Maduck | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.97 per share. | 02 Mar 2026 | 110 | 8,977 (0%) | 0% | 36.0 | 3,957 | - |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | 27 Feb 2026 | 460,000 | 460,000 | - | - | Stock Option (right to buy) | ||
| Mr. G. Charles Robb | Chief Business Officer | 27 Feb 2026 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | ||
| Mr. Atabak Mokari | Chief Financial Officer | 27 Feb 2026 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | ||
| Mr. Sean Maduck | See Remarks | 27 Feb 2026 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | ||
| Mr. Joseph Douglas Lyon | See Remarks | 27 Feb 2026 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | ||
| Dr. Hazel Hunt, PhD | Chief Scientific Officer | 27 Feb 2026 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 27 Feb 2026 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | ||
| Mr. James N. Wilson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 24 Feb 2026 | 100,000 | 100,000 (0%) | 0% | 3.9 | 388,000 | Common Stock |
| Mr. James N. Wilson | Director | 24 Feb 2026 | 100,000 | 0 | - | - | Stock option (right to buy) | ||
| Mr. James N. Wilson | Director | Other type of transaction at price $ 0.00 per share. | 24 Feb 2026 | 89,364 | 1,134,532 (0%) | 0% | 0 | Common Stock | |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Feb 2026 | 89,364 | 0 (0%) | 0% | 0 | Common Stock | |
| Mr. James N. Wilson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.48 per share. | 24 Feb 2026 | 10,636 | 89,364 (0%) | 0% | 36.5 | 388,001 | Common Stock |
| Mr. James N. Wilson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 24 Feb 2026 | 100,000 | 100,000 (0%) | 0% | 3.9 | 388,000 | - |
| Mr. James N. Wilson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.48 per share. | 24 Feb 2026 | 10,636 | 89,364 (0%) | 0% | 36.5 | 388,001 | - |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Feb 2026 | 89,364 | 0 (0%) | 0% | 0 | - | |
| Mr. James N. Wilson | Director | Other type of transaction at price $ 0.00 per share. | 24 Feb 2026 | 89,364 | 1,134,532 (0%) | 0% | 0 | - | |
| Mr. James N. Wilson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 24 Feb 2026 | 100,000 | 100,000 (0%) | 0% | 3.9 | 388,000 | - |
| Mr. James N. Wilson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.48 per share. | 24 Feb 2026 | 10,636 | 89,364 (0%) | 0% | 36.5 | 388,001 | - |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Feb 2026 | 89,364 | 0 (0%) | 0% | 0 | - | |
| Mr. James N. Wilson | Director | Other type of transaction at price $ 0.00 per share. | 24 Feb 2026 | 89,364 | 1,134,532 (0%) | 0% | 0 | - | |
| Dr. Hazel Hunt, PhD | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 09 Feb 2026 | 150,000 | 333,405 (0%) | 0% | 3.9 | 582,000 | - |
| Dr. Hazel Hunt, PhD | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.31 per share. | 09 Feb 2026 | 77,968 | 255,437 (0%) | 0% | 41.3 | 3,220,858 | - |
| Dr. Hazel Hunt, PhD | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.31 per share. | 09 Feb 2026 | 77,968 | 255,437 (0%) | 0% | 41.3 | 3,220,858 | Common Stock |
| Dr. Hazel Hunt, PhD | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 09 Feb 2026 | 150,000 | 333,405 (0%) | 0% | 3.9 | 582,000 | Common Stock |
| Dr. Hazel Hunt, PhD | Chief Scientific Officer | 09 Feb 2026 | 150,000 | 0 | - | - | Stock Option (right to buy) | ||
| Dr. Hazel Hunt, PhD | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 09 Feb 2026 | 150,000 | 333,405 (0%) | 0% | 3.9 | 582,000 | - |
| Dr. Hazel Hunt, PhD | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.31 per share. | 09 Feb 2026 | 77,968 | 255,437 (0%) | 0% | 41.3 | 3,220,858 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 03 Feb 2026 | 20,000 | 21,235 (0%) | 0% | 21.7 | 433,000 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 03 Feb 2026 | 20,000 | 230,000 | - | - | Stock option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 40.87 per share. | 03 Feb 2026 | 20,000 | 1,235 (0%) | 0% | 40.9 | 817,334 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 03 Feb 2026 | 20,000 | 21,235 (0%) | 0% | 21.7 | 433,000 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 40.87 per share. | 03 Feb 2026 | 20,000 | 1,235 (0%) | 0% | 40.9 | 817,334 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 03 Feb 2026 | 20,000 | 21,235 (0%) | 0% | 21.7 | 433,000 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 40.87 per share. | 03 Feb 2026 | 20,000 | 1,235 (0%) | 0% | 40.9 | 817,334 | - |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.86 per share. | 27 Jan 2026 | 30,000 | 985,262 (0%) | 0% | 5.9 | 175,800 | - |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.13 per share. | 27 Jan 2026 | 30,000 | 1,015,262 (0%) | 0% | 12.1 | 363,900 | - |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.08 per share. | 27 Jan 2026 | 25,000 | 1,040,262 (0%) | 0% | 14.1 | 352,000 | - |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.50 per share. | 27 Jan 2026 | 25,000 | 1,065,262 (0%) | 0% | 10.5 | 262,500 | - |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.15 per share. | 27 Jan 2026 | 30,000 | 1,095,262 (0%) | 0% | 15.2 | 454,500 | - |
| Mr. George Leonard Baker, Jr | Director | 27 Jan 2026 | 30,000 | 0 | - | - | Stock Option (Right To Buy) | ||
| Mr. George Leonard Baker, Jr | Director | 27 Jan 2026 | 30,000 | 0 | - | - | Stock Option (Right To Buy) | ||
| Mr. George Leonard Baker, Jr | Director | 27 Jan 2026 | 30,000 | 0 | - | - | Stock Option (Right To Buy) | ||
| Mr. George Leonard Baker, Jr | Director | 27 Jan 2026 | 25,000 | 0 | - | - | Stock Option (Right To Buy) | ||
| Mr. George Leonard Baker, Jr | Director | 27 Jan 2026 | 25,000 | 0 | - | - | Stock Option (Right To Buy) | ||
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.86 per share. | 27 Jan 2026 | 30,000 | 985,262 (0%) | 0% | 5.9 | 175,800 | Common Stock |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.13 per share. | 27 Jan 2026 | 30,000 | 1,015,262 (0%) | 0% | 12.1 | 363,900 | Common Stock |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.08 per share. | 27 Jan 2026 | 25,000 | 1,040,262 (0%) | 0% | 14.1 | 352,000 | Common Stock |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.50 per share. | 27 Jan 2026 | 25,000 | 1,065,262 (0%) | 0% | 10.5 | 262,500 | Common Stock |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.15 per share. | 27 Jan 2026 | 30,000 | 1,095,262 (0%) | 0% | 15.2 | 454,500 | Common Stock |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.86 per share. | 27 Jan 2026 | 30,000 | 985,262 (0%) | 0% | 5.9 | 175,800 | - |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.13 per share. | 27 Jan 2026 | 30,000 | 1,015,262 (0%) | 0% | 12.1 | 363,900 | - |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.08 per share. | 27 Jan 2026 | 25,000 | 1,040,262 (0%) | 0% | 14.1 | 352,000 | - |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.50 per share. | 27 Jan 2026 | 25,000 | 1,065,262 (0%) | 0% | 10.5 | 262,500 | - |
| Mr. George Leonard Baker, Jr | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.15 per share. | 27 Jan 2026 | 30,000 | 1,095,262 (0%) | 0% | 15.2 | 454,500 | - |
| Mr. Sean Maduck | See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Jan 2026 | 34,000 | 5,147 (0%) | 0% | 0 | Common Stock | |
| Mr. Sean Maduck | See Remarks | Other type of transaction at price $ 0.00 per share. | 08 Jan 2026 | 34,000 | 34,000 (0%) | 0% | 0 | Common Stock | |
| Mr. Sean Maduck | See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Jan 2026 | 20,570 | 39,147 (0%) | 0% | 0 | Common Stock | |
| Mr. Sean Maduck | See Remarks | Other type of transaction at price $ 0.00 per share. | 08 Jan 2026 | 20,570 | 20,570 (0%) | 0% | 0 | Common Stock | |
| Mr. Sean Maduck | See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Jan 2026 | 20,570 | 39,147 (0%) | 0% | 0 | - | |
| Mr. Sean Maduck | See Remarks | Other type of transaction at price $ 0.00 per share. | 08 Jan 2026 | 20,570 | 20,570 (0%) | 0% | 0 | - | |
| Mr. Sean Maduck | See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Jan 2026 | 34,000 | 5,147 (0%) | 0% | 0 | - | |
| Mr. Sean Maduck | See Remarks | Other type of transaction at price $ 0.00 per share. | 08 Jan 2026 | 34,000 | 34,000 (0%) | 0% | 0 | - | |
| Mr. Sean Maduck | See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Jan 2026 | 20,570 | 39,147 (0%) | 0% | 0 | - | |
| Mr. Sean Maduck | See Remarks | Other type of transaction at price $ 0.00 per share. | 08 Jan 2026 | 20,570 | 20,570 (0%) | 0% | 0 | - | |
| Mr. Sean Maduck | See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Jan 2026 | 34,000 | 5,147 (0%) | 0% | 0 | - | |
| Mr. Sean Maduck | See Remarks | Other type of transaction at price $ 0.00 per share. | 08 Jan 2026 | 34,000 | 34,000 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 06 Jan 2026 | 20,000 | 21,235 (0%) | 0% | 21.7 | 433,000 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 35.18 per share. | 06 Jan 2026 | 20,000 | 1,235 (0%) | 0% | 35.2 | 703,656 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 06 Jan 2026 | 20,000 | 21,235 (0%) | 0% | 21.7 | 433,000 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 35.18 per share. | 06 Jan 2026 | 20,000 | 1,235 (0%) | 0% | 35.2 | 703,656 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 06 Jan 2026 | 20,000 | 250,000 | - | - | Stock option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 06 Jan 2026 | 20,000 | 21,235 (0%) | 0% | 21.7 | 433,000 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 35.18 per share. | 06 Jan 2026 | 20,000 | 1,235 (0%) | 0% | 35.2 | 703,656 | - |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.59 per share. | 24 Dec 2025 | 306,846 | 243,154 (0%) | 0% | 83.6 | 25,649,257 | Common Stock |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | 24 Dec 2025 | 550,000 | 0 | - | - | Stock option (right to buy) | ||
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 24 Dec 2025 | 243,154 | 2,944,524 (2%) | 0% | 0 | Common Stock | |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Dec 2025 | 243,154 | 0 (0%) | 0% | 0 | Common Stock | |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 24 Dec 2025 | 550,000 | 550,000 (0%) | 0% | 3.9 | 2,134,000 | Common Stock |
| Mr. G. Charles Robb | Chief Business Officer | 24 Dec 2025 | 145,000 | 0 | - | - | Stock option (right to buy) | ||
| Mr. G. Charles Robb | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.59 per share. | 24 Dec 2025 | 80,284 | 78,626 (0%) | 0% | 83.6 | 6,710,940 | Common Stock |
| Mr. G. Charles Robb | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 24 Dec 2025 | 145,000 | 158,910 (0%) | 0% | 3.9 | 562,600 | Common Stock |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 24 Dec 2025 | 550,000 | 550,000 (0%) | 0% | 3.9 | 2,134,000 | - |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.59 per share. | 24 Dec 2025 | 306,846 | 243,154 (0%) | 0% | 83.6 | 25,649,257 | - |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Dec 2025 | 243,154 | 0 (0%) | 0% | 0 | - | |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 24 Dec 2025 | 243,154 | 2,944,524 (2%) | 0% | 0 | - | |
| Mr. G. Charles Robb | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 24 Dec 2025 | 145,000 | 158,910 (0%) | 0% | 3.9 | 562,600 | - |
| Mr. G. Charles Robb | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.59 per share. | 24 Dec 2025 | 80,284 | 78,626 (0%) | 0% | 83.6 | 6,710,940 | - |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 24 Dec 2025 | 550,000 | 550,000 (0%) | 0% | 3.9 | 2,134,000 | - |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.59 per share. | 24 Dec 2025 | 306,846 | 243,154 (0%) | 0% | 83.6 | 25,649,257 | - |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Dec 2025 | 243,154 | 0 (0%) | 0% | 0 | - | |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Other type of transaction at price $ 0.00 per share. | 24 Dec 2025 | 243,154 | 2,944,524 (2%) | 0% | 0 | - | |
| Mr. G. Charles Robb | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.88 per share. | 24 Dec 2025 | 145,000 | 158,910 (0%) | 0% | 3.9 | 562,600 | - |
| Mr. G. Charles Robb | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.59 per share. | 24 Dec 2025 | 80,284 | 78,626 (0%) | 0% | 83.6 | 6,710,940 | - |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2025 | 400,000 | 1,045,168 (0%) | 0% | 0 | - | |
| Mr. James N. Wilson | Director | Other type of transaction at price $ 0.00 per share. | 12 Dec 2025 | 200,000 | 200,000 (0%) | 0% | 0 | - | |
| Mr. James N. Wilson | Director | Other type of transaction at price $ 0.00 per share. | 12 Dec 2025 | 200,000 | 200,000 (0%) | 0% | 0 | - | |
| Mr. James N. Wilson | Director | Other type of transaction at price $ 0.00 per share. | 12 Dec 2025 | 200,000 | 200,000 (0%) | 0% | 0 | Common Stock | |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2025 | 400,000 | 1,045,168 (0%) | 0% | 0 | Common Stock | |
| Mr. James N. Wilson | Director | Other type of transaction at price $ 0.00 per share. | 12 Dec 2025 | 200,000 | 200,000 (0%) | 0% | 0 | Common Stock | |
| Mr. James N. Wilson | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 12 Dec 2025 | 400,000 | 1,045,168 (0%) | 0% | 0 | - | |
| Mr. James N. Wilson | Director | Other type of transaction at price $ 0.00 per share. | 12 Dec 2025 | 200,000 | 200,000 (0%) | 0% | 0 | - | |
| Mr. James N. Wilson | Director | Other type of transaction at price $ 0.00 per share. | 12 Dec 2025 | 200,000 | 200,000 (0%) | 0% | 0 | - | |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 79.77 per share. | 01 Dec 2025 | 40,000 | 2,701,370 (2%) | 0% | 79.8 | 3,190,796 | Common Stock |
| Mr. G. Charles Robb | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 148 | 13,910 (0%) | 0% | 79.8 | 11,807 | Common Stock |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 224 | 14,058 (0%) | 0% | 0 | Common Stock | |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 224 | 13,834 (0%) | 0% | 79.8 | 17,871 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 118 | 14,559 (0%) | 0% | 79.8 | 9,414 | Common Stock |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 178 | 14,677 (0%) | 0% | 0 | Common Stock | |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 178 | 14,499 (0%) | 0% | 79.8 | 14,201 | Common Stock |
| Mr. Sean Maduck | See Remarks | 01 Dec 2025 | 20,000 | 241,986 | - | - | Stock option (right to buy) | ||
| Mr. Sean Maduck | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 135 | 8,179 (0%) | 0% | 79.8 | 10,770 | Common Stock |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 205 | 8,314 (0%) | 0% | 0 | Common Stock | |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 205 | 8,109 (0%) | 0% | 79.8 | 16,355 | Common Stock |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 79.52 per share. | 01 Dec 2025 | 20,000 | 7,904 (0%) | 0% | 79.5 | 1,590,490 | Common Stock |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 01 Dec 2025 | 20,000 | 27,904 (0%) | 0% | 8.3 | 165,400 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | 01 Dec 2025 | 5,000 | 11,571 | - | - | Stock option (right to buy) | ||
| Mr. Joseph Douglas Lyon | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 110 | 10,523 (0%) | 0% | 79.8 | 8,776 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 178 | 10,633 (0%) | 0% | 0 | Common Stock | |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 178 | 10,455 (0%) | 0% | 79.8 | 14,201 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | Sale of securities on an exchange or to another person at price $ 79.53 per share. | 01 Dec 2025 | 5,000 | 10,277 (0%) | 0% | 79.5 | 397,632 | Common Stock |
| Mr. Joseph Douglas Lyon | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.56 per share. | 01 Dec 2025 | 5,000 | 15,277 (0%) | 0% | 13.6 | 67,800 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Other type of transaction at price $ 0.00 per share. | 01 Dec 2025 | 787 | 1,235 (0%) | 0% | 0 | Common Stock | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 01 Dec 2025 | 20,000 | 270,000 | - | - | Stock option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.88 per share. | 01 Dec 2025 | 640 | 1,235 (0%) | 0% | 80.9 | 51,760 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.05 per share. | 01 Dec 2025 | 19,360 | 1,875 (0%) | 0% | 80.0 | 1,549,766 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 224 | 448 (0%) | 0% | 0 | Common Stock | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 01 Dec 2025 | 20,000 | 21,235 (0%) | 0% | 21.7 | 433,000 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Dec 2025 | 787 | 0 (0%) | 0% | 0 | Common Stock | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 224 | 224 (0%) | 0% | 79.8 | 17,871 | Common Stock |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 79.77 per share. | 01 Dec 2025 | 40,000 | 2,701,370 (2%) | 0% | 79.8 | 3,190,796 | - |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 224 | 13,834 (0%) | 0% | 79.8 | 17,871 | - |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 224 | 14,058 (0%) | 0% | 0 | - | |
| Mr. G. Charles Robb | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 148 | 13,910 (0%) | 0% | 79.8 | 11,807 | - |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 178 | 14,499 (0%) | 0% | 79.8 | 14,201 | - |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 178 | 14,677 (0%) | 0% | 0 | - | |
| Mr. Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 118 | 14,559 (0%) | 0% | 79.8 | 9,414 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.56 per share. | 01 Dec 2025 | 5,000 | 15,277 (0%) | 0% | 13.6 | 67,800 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Sale of securities on an exchange or to another person at price $ 79.53 per share. | 01 Dec 2025 | 5,000 | 10,277 (0%) | 0% | 79.5 | 397,632 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 178 | 10,455 (0%) | 0% | 79.8 | 14,201 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 178 | 10,633 (0%) | 0% | 0 | - | |
| Mr. Joseph Douglas Lyon | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 110 | 10,523 (0%) | 0% | 79.8 | 8,776 | - |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 01 Dec 2025 | 20,000 | 27,904 (0%) | 0% | 8.3 | 165,400 | - |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 79.52 per share. | 01 Dec 2025 | 20,000 | 7,904 (0%) | 0% | 79.5 | 1,590,490 | - |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 205 | 8,109 (0%) | 0% | 79.8 | 16,355 | - |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 205 | 8,314 (0%) | 0% | 0 | - | |
| Mr. Sean Maduck | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 135 | 8,179 (0%) | 0% | 79.8 | 10,770 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 224 | 224 (0%) | 0% | 79.8 | 17,871 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 224 | 448 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Dec 2025 | 787 | 0 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Other type of transaction at price $ 0.00 per share. | 01 Dec 2025 | 787 | 1,235 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 01 Dec 2025 | 20,000 | 21,235 (0%) | 0% | 21.7 | 433,000 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.05 per share. | 01 Dec 2025 | 19,360 | 1,875 (0%) | 0% | 80.0 | 1,549,766 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.88 per share. | 01 Dec 2025 | 640 | 1,235 (0%) | 0% | 80.9 | 51,760 | - |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 79.77 per share. | 01 Dec 2025 | 40,000 | 2,701,370 (2%) | 0% | 79.8 | 3,190,796 | - |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 224 | 13,834 (0%) | 0% | 79.8 | 17,871 | - |
| Mr. G. Charles Robb | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 224 | 14,058 (0%) | 0% | 0 | - | |
| Mr. G. Charles Robb | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 148 | 13,910 (0%) | 0% | 79.8 | 11,807 | - |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 178 | 14,499 (0%) | 0% | 79.8 | 14,201 | - |
| Mr. Atabak Mokari | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 178 | 14,677 (0%) | 0% | 0 | - | |
| Mr. Atabak Mokari | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 118 | 14,559 (0%) | 0% | 79.8 | 9,414 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.56 per share. | 01 Dec 2025 | 5,000 | 15,277 (0%) | 0% | 13.6 | 67,800 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Sale of securities on an exchange or to another person at price $ 79.53 per share. | 01 Dec 2025 | 5,000 | 10,277 (0%) | 0% | 79.5 | 397,632 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 178 | 10,455 (0%) | 0% | 79.8 | 14,201 | - |
| Mr. Joseph Douglas Lyon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 178 | 10,633 (0%) | 0% | 0 | - | |
| Mr. Joseph Douglas Lyon | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 110 | 10,523 (0%) | 0% | 79.8 | 8,776 | - |
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 01 Dec 2025 | 20,000 | 27,904 (0%) | 0% | 8.3 | 165,400 | - |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 79.52 per share. | 01 Dec 2025 | 20,000 | 7,904 (0%) | 0% | 79.5 | 1,590,490 | - |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 205 | 8,109 (0%) | 0% | 79.8 | 16,355 | - |
| Mr. Sean Maduck | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 205 | 8,314 (0%) | 0% | 0 | - | |
| Mr. Sean Maduck | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.78 per share. | 01 Dec 2025 | 135 | 8,179 (0%) | 0% | 79.8 | 10,770 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 79.78 per share. | 01 Dec 2025 | 224 | 224 (0%) | 0% | 79.8 | 17,871 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 224 | 448 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 01 Dec 2025 | 787 | 0 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Other type of transaction at price $ 0.00 per share. | 01 Dec 2025 | 787 | 1,235 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 01 Dec 2025 | 20,000 | 21,235 (0%) | 0% | 21.7 | 433,000 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.05 per share. | 01 Dec 2025 | 19,360 | 1,875 (0%) | 0% | 80.0 | 1,549,766 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.88 per share. | 01 Dec 2025 | 640 | 1,235 (0%) | 0% | 80.9 | 51,760 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.90 per share. | 25 Nov 2025 | 4,500 | 787 (0%) | 0% | 80.9 | 364,070 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.90 per share. | 25 Nov 2025 | 4,500 | 787 (0%) | 0% | 80.9 | 364,070 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.90 per share. | 25 Nov 2025 | 4,500 | 787 (0%) | 0% | 80.9 | 364,070 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.90 per share. | 17 Nov 2025 | 4,500 | 787 (0%) | 0% | 80.9 | 364,070 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Other type of transaction at price $ 0.00 per share. | 17 Nov 2025 | 5,287 | 5,287 (0%) | 0% | 0 | Common Stock | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Nov 2025 | 5,287 | 0 (0%) | 0% | 0 | Common Stock | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Nov 2025 | 5,287 | 0 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Other type of transaction at price $ 0.00 per share. | 17 Nov 2025 | 5,287 | 5,287 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.90 per share. | 17 Nov 2025 | 4,500 | 787 (0%) | 0% | 80.9 | 364,070 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 Nov 2025 | 5,287 | 0 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Other type of transaction at price $ 0.00 per share. | 17 Nov 2025 | 5,287 | 5,287 (0%) | 0% | 0 | - | |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 80.90 per share. | 17 Nov 2025 | 4,500 | 787 (0%) | 0% | 80.9 | 364,070 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 05 Nov 2025 | 20,000 | 25,287 (0%) | 0% | 21.7 | 433,000 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 74.75 per share. | 05 Nov 2025 | 6,536 | 18,751 (0%) | 0% | 74.7 | 488,559 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.64 per share. | 05 Nov 2025 | 13,164 | 5,587 (0%) | 0% | 75.6 | 995,679 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 76.28 per share. | 05 Nov 2025 | 300 | 5,287 (0%) | 0% | 76.3 | 22,884 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 05 Nov 2025 | 20,000 | 25,287 (0%) | 0% | 21.7 | 433,000 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | 05 Nov 2025 | 20,000 | 290,000 | - | - | Stock option (right to buy) | ||
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 76.28 per share. | 05 Nov 2025 | 300 | 5,287 (0%) | 0% | 76.3 | 22,884 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.64 per share. | 05 Nov 2025 | 13,164 | 5,587 (0%) | 0% | 75.6 | 995,679 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 74.75 per share. | 05 Nov 2025 | 6,536 | 18,751 (0%) | 0% | 74.7 | 488,559 | Common Stock |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.65 per share. | 05 Nov 2025 | 20,000 | 25,287 (0%) | 0% | 21.7 | 433,000 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 74.75 per share. | 05 Nov 2025 | 6,536 | 18,751 (0%) | 0% | 74.7 | 488,559 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 75.64 per share. | 05 Nov 2025 | 13,164 | 5,587 (0%) | 0% | 75.6 | 995,679 | - |
| Dr. William Guyer, Pharm.D. | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 76.28 per share. | 05 Nov 2025 | 300 | 5,287 (0%) | 0% | 76.3 | 22,884 | - |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.08 per share. | 03 Nov 2025 | 11,218 | 2,770,152 (2%) | 0% | 74.1 | 831,014 | Common Stock |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.98 per share. | 03 Nov 2025 | 3,590 | 2,741,370 (2%) | 0% | 76.0 | 272,760 | Common Stock |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 75.14 per share. | 03 Nov 2025 | 10,837 | 2,744,960 (2%) | 0% | 75.1 | 814,262 | Common Stock |
| Dr. Joseph K. Belanoff, M.D. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 74.20 per share. | 03 Nov 2025 | 14,355 | 2,755,797 (2%) | 0% | 74.2 | 1,065,084 | Common Stock |
| Mr. Sean Maduck | See Remarks | 03 Nov 2025 | 20,000 | 261,986 | - | - | Stock option (right to buy) | ||
| Mr. Sean Maduck | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 03 Nov 2025 | 20,000 | 27,904 (0%) | 0% | 8.3 | 165,400 | Common Stock |
| Mr. Sean Maduck | See Remarks | Sale of securities on an exchange or to another person at price $ 73.99 per share. | 03 Nov 2025 | 20,000 | 7,904 (0%) | 0% | 74.0 | 1,479,816 | Common Stock |